Zacks Research Analysts Boost Earnings Estimates for PBYI

Puma Biotechnology, Inc. (NASDAQ:PBYI) – Zacks Research increased their Q4 2025 earnings per share estimates for Puma Biotechnology in a report released on Wednesday, January 22nd. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earnings per share of $0.16 for the quarter, up from their prior estimate of $0.13. The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.31 per share. Zacks Research also issued estimates for Puma Biotechnology’s Q2 2026 earnings at $0.01 EPS and Q3 2026 earnings at $0.11 EPS.

Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.10. The company had revenue of $80.50 million during the quarter, compared to the consensus estimate of $71.32 million. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. During the same quarter last year, the company earned $0.12 earnings per share.

A number of other analysts have also issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Puma Biotechnology in a research report on Monday, December 23rd. StockNews.com lowered Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 6th.

Puma Biotechnology Stock Performance

Puma Biotechnology stock opened at $2.96 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 1.40. The firm’s fifty day moving average price is $3.06 and its 200 day moving average price is $2.99. The company has a market capitalization of $145.30 million, a price-to-earnings ratio of 6.17 and a beta of 1.10. Puma Biotechnology has a 12-month low of $2.22 and a 12-month high of $7.73.

Insider Buying and Selling at Puma Biotechnology

In other news, insider Jeffrey Jerome Ludwig sold 9,437 shares of Puma Biotechnology stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total value of $29,726.55. Following the completion of the transaction, the insider now owns 108,951 shares in the company, valued at approximately $343,195.65. This trade represents a 7.97 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Alan H. Auerbach sold 33,841 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total value of $106,599.15. Following the sale, the chief executive officer now directly owns 7,029,674 shares in the company, valued at approximately $22,143,473.10. This represents a 0.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 23.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Puma Biotechnology

A number of large investors have recently bought and sold shares of PBYI. Gateway Wealth Partners LLC acquired a new position in Puma Biotechnology during the 4th quarter valued at approximately $31,000. SG Americas Securities LLC acquired a new position in shares of Puma Biotechnology during the third quarter valued at $34,000. Franklin Resources Inc. bought a new position in shares of Puma Biotechnology during the third quarter worth about $41,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Puma Biotechnology in the 3rd quarter worth about $44,000. Finally, Patriot Financial Group Insurance Agency LLC increased its holdings in shares of Puma Biotechnology by 72.7% in the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 19,000 shares of the biopharmaceutical company’s stock worth $48,000 after acquiring an additional 8,000 shares during the period. Institutional investors own 61.29% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.